MRVI241220C2500
- 2.20
- 0.000.00%
Maravai LifeSciences Newsroom
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating
Craig-Hallum Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)
Maravai Lifesciences Chairman Carl Hull to Retire, R. Andrew Eckert to Succeed
Maravai LifeSciences Appoints R. Andrew Eckert as New Chairman of the Board Following Carl Hull's Retirement
Maravai LifeSciences: Carl Hull to Retire as Executive Chairman >MRVI
Express News | Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
Press Release: Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
4 Analysts Have This To Say About Maravai LifeSciences
Goldman Sachs Downgrades Maravai LifeSciences(MRVI.US) to Sell Rating
Goldman Sachs Downgrades Maravai Lifesciences to Sell From Neutral, Cuts Price Target to $4.25 From $7
Co-Founder & Executive Chairman of Maravai LifeSciences Holdings Carl Hull Buys 174% More Shares
Maravai LifeSciences Initiated at Peer Perform by Wolfe Research
Maravai LifeSciences Analyst Ratings
Wolfe Research Initiates Maravai LifeSciences(MRVI.US) With Hold Rating
Estimating The Fair Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Maravai LifeSciences | 10-Q: Q3 2024 Earnings Report
Maravai LifeSciences Announces November 2024 Investor Conference Schedule
Morgan Stanley Maintains Maravai LifeSciences(MRVI.US) With Hold Rating, Cuts Target Price to $7
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript Summary
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript